Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Optimizing HIV prevention and treatment outcomes for persons with substance use in Central Asia: what will it take?

Optimizing HIV prevention and treatment outcomes for persons with substance use in Central Asia:... Purpose of review To summarize the status of HIV and substance use in Central Asia and discuss potential ways to move forward to effective epidemic control among people who inject drugs (PWID) in the region and beyond. Recent findings PWID and their partners remain the population most affected by HIV in Central Asia. Lack of effective substance use prevention and treatment options and limited involvement of PWID-led community-based organizations in HIV programs, combined with the requirement for official registration, stigma and discrimination of PWID, and criminalization of drug use remain key barriers to effective HIV prevention and treatment. Summary Sustainable HIV epidemic control among PWID will not be feasible without decriminalization of drug use, addressing stigma and discrimination and policy changes to enhance uptake of HIV-related prevention, treatment and support services by PWID. It is also critical to ensure adoption of innovations, particularly those that combine evidence-based biomedical, behavioral and structural interventions tailored to the needs of the PWID. ICAP at Columbia University, Mailman School of Public Health, Columbia University, Almaty, Kazakhstan Correspondence to Anna P. Deryabina, 34/1 Samal -3, Almaty 050051, Kazakhstan. Tel: +7 727 2631572; e-mail: annaderyabina@icap.kz This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Optimizing HIV prevention and treatment outcomes for persons with substance use in Central Asia: what will it take?

Loading next page...
 
/lp/wolters-kluwer-health/optimizing-hiv-prevention-and-treatment-outcomes-for-persons-with-WU8OVYePyp

References (64)

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000565
Publisher site
See Article on Publisher Site

Abstract

Purpose of review To summarize the status of HIV and substance use in Central Asia and discuss potential ways to move forward to effective epidemic control among people who inject drugs (PWID) in the region and beyond. Recent findings PWID and their partners remain the population most affected by HIV in Central Asia. Lack of effective substance use prevention and treatment options and limited involvement of PWID-led community-based organizations in HIV programs, combined with the requirement for official registration, stigma and discrimination of PWID, and criminalization of drug use remain key barriers to effective HIV prevention and treatment. Summary Sustainable HIV epidemic control among PWID will not be feasible without decriminalization of drug use, addressing stigma and discrimination and policy changes to enhance uptake of HIV-related prevention, treatment and support services by PWID. It is also critical to ensure adoption of innovations, particularly those that combine evidence-based biomedical, behavioral and structural interventions tailored to the needs of the PWID. ICAP at Columbia University, Mailman School of Public Health, Columbia University, Almaty, Kazakhstan Correspondence to Anna P. Deryabina, 34/1 Samal -3, Almaty 050051, Kazakhstan. Tel: +7 727 2631572; e-mail: annaderyabina@icap.kz This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: Sep 1, 2019

There are no references for this article.